Market Research Report
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) 2018
|Published by||FirstWord||Product code||593152|
Delivery time: 1-2 business days
|Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US) 2018|
|Published: April 1, 2018||Content info:||
Market barriers only affect over a third of oral diabetes treatment prescriptions in the US. Is your brand losing out?
Market barriers affect over a third of all oral type 2 diabetes mellitus (T2DM) prescriptions in the US, and certain brands are losing out on market share big time. Is it yours? Find out what's driving share gains, and what your brand can do to level the playing field in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) .
Based on a survey of 100 diabetologists, the report covers 9 major oral therapies from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Johnson & Johnson, Merck & Co., and Takeda. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 9 Oral Type 2 Diabetes Mellitus Treatments
Exploring Market Access Barriers
Market Access Impact: Type 2 Diabetes Mellitus [Orals] (US)  explores key issues affecting type 2 diabetes mellitus drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 100 US-based diabetologists and primary care physicians, chosen from the largest community of validated physicians in the world. All respondents have:
We conducted the survey between April 5-10, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.